EC approves two-drug tablet for HIV from ViiV, Janssen

ViiV Healthcare Ltd. (Brentford, U.K.) and Janssen Pharmaceutical Co. said the European Commission approved Juluca dolutegravir/rilpivirine to treat HIV-1 infection. The companies said Juluca, which FDA approved last year, is the first single-tablet, two-drug regimen that is approved for HIV maintenance. Current standard HIV treatments include three or more drugs.

Juluca is indicated for patients with HIV-1 infection who are virally suppressed on a stable regimen for at least six months with no history of treatment failure and no known or suspected resistance to a non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor...